Kristen Hege, MD - 2021 World Medical Innovation Forum
May 2–4, 2022
Kristen Hege
This speaker appears at this event:

This speaker appears in these events:

Kristen Hege, MD

Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, BMS

Dr. Hege is SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb (BMS). Previously, she spent 10 years at Celgene where her team advanced a pipeline of small molecules, biologics and T cell therapies. She has led the bluebird-partnered BCMA CART cell program (ide-cel) in multiple myeloma from inception through FDA approval. Prior to joining Celgene she held multiple executive roles at Cell Genesys, Cellerant, and Theraclone.
In addition to her work at BMS, Dr. Hege is a Clinical Professor of Medicine at UCSF where she continues to see patients with blood cancers weekly. Dr. Hege also serves on the Board of Directors of Mersana Therapeutics and was elected to the Board of Directors for the Society for Immunotherapy of Cancer (SITC) for a 3-year term from 2016-2019.
Dr. Hege received her M.D. at UCSF and residency and hematology/oncology subspecialty training at Harvard and UCSF, respectively. In 2015, she was recognized by Fierce Biotech as one of the top 12 women in Biopharma. Her career path and long history with CAR T cell development was featured as part of the 25th anniversary celebration of Nature Medicine.

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA